GAMMA Investing LLC Raises Position in Danaher Co. (NYSE:DHR)

GAMMA Investing LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 66.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,466 shares of the conglomerate’s stock after purchasing an additional 2,986 shares during the quarter. GAMMA Investing LLC’s holdings in Danaher were worth $1,714,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Danaher in the second quarter valued at $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher during the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Danaher during the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DHR shares. Barclays dropped their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. UBS Group cut their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. TD Cowen lifted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $287.05.

Danaher Stock Up 2.2 %

Shares of DHR stock opened at $234.84 on Friday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The firm has a market capitalization of $169.62 billion, a PE ratio of 44.82, a P/E/G ratio of 4.33 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock’s 50-day simple moving average is $236.58 and its 200-day simple moving average is $254.47.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period last year, the firm posted $2.02 EPS. Equities analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.